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Various chemokines and cytokines as adjuvants can be used to improve eﬃcacy of DNA vaccination. In this study, we sought to
investigate if a DNA construct expressing IL-9 (designed as proV-IL9) as a molecular adjuvant enhance antigen speciﬁc immune
responses elicited by the pcD-VP1 DNA vaccination. Mice immunized with pcD-VP1 combined with proV-IL9 developed a strong
humoralresponse.Inaddition,thecoinoculationinducedsigniﬁcanthigherlevelofantigen-speciﬁccellproliferationandcytotoxic
response. This agreed well with higher expression level of IFN-γ a n dp e r f o r i ni nC D 8 + T cells, but not with IL-17 in these T cells.
The results indicate that IL-9 induces the development of IFN-γ-producing CD8+ T cells (Tc1), but not the IL-17-producing
CD8+ T cells (Tc17). Up-regulated expressions of BCL-2 and BCL-XL were exhibited in these Tc1 cells, suggesting that IL-9 may
trigger antiapoptosis mechanism in these cells. Together, these results demonstrated that IL-9 used as molecular adjuvant could
enhance the immunogenicity of DNA vaccination, in augmenting humoral and cellular responses and particularly promoting Tc1
activations. Thus, the IL-9 may be utilized as a potent Tc1 adjuvant for DNA vaccines.
1.Introduction
Foot and mouth disease virus (FMDV) is a member of
genus Aphthovirus in the family Picornaviridae and causes a
great economical loss for farm animals [1]. Since the current
available inactivated FMDV vaccine is still considered as a
potential outbreak, alternative vaccination methods should
be developed [2]. DNA vaccination oﬀers one of such
alternatives, which is a relatively novel and powerful method
of immunization, capable of humoral as well as cellular
immunity [3–6]. To date, various approaches have been
developed to enhance the immunogenicity of plasmid DNA
vaccines, such as the use of plasmid expressing cytokine as a
molecular adjuvant [7, 8].
IL-9, a cytokine produced by T cells, mast cells,
eosinophils, and neutrophils, stimulates cell proliferation
and prevents apoptosis [9]. In addition, IL-9 supports the
growth of T cells and also increases the production of
IL-6 in B lymphocytes in a phenomenon culminating in
an enhancement of IgE or IgG1 synthesis [10, 11]. IL-9
producing-DC can be used to induce protective immune
response against intestinal nematodes [12].
In spite of its immune eﬀects, IL-9 or its expressing
construct has not been examined to determine if it can
be used as adjuvant, directly aﬀecting elicited immune
responses of vaccines. In this study, we demonstrated that
coinoculation of the IL-9 expressing construct with VP1
DNA vaccine, encoding VP1 capsid protein of foot-and-
mouth disease virus, induced strong humoral and cellular
immune responses, including the antigen-speciﬁc CD8 Tc1
activation.
2.MaterialsandMethods
2.1. Reagents and Animals. FMDV VP1 peptide representing
the T-cell epitope (aa133–147, SSKYGDTSTNNVRGD) was2 Journal of Biomedicine and Biotechnology
Table 1: Immunization groups.
Groups DNA vaccine Adjuvant
1N a ¨ ıve
2 100μg pcD 100μgp r o V
3 100μg pcD 100μgp r o V - I L 9
4 100μg pcD-VP1 100μgp r o V
5 100μg pcD-VP1 100μgp r o V - I L 9
N o t e :p c Da n dp r o Va r ee m p t yv e c t o r s .
synthesized by GL Biochem Co., Ltd. (Shanghai, China).
Conjugated Abs used for ﬂow cytometry analysis were
purchased from BD Pharmingen (San Diego, USA). Adult
female C57BL/6 mice at 8–10 weeks of age were purchased
from Animal Institute of Chinese Medical Academy (Beijing,
China) and feed with pathogen-free food and water in a 12-h
light-cycle.
2.2. Plasmid Construction and Preparations. The pcD-VP1
was constructed into pcDNA3.0 as described previously
[13]. The coding sequence for mouse IL-9 was obtained
from mRNA isolated from spleens by RT-PCR method and
subcloned into the proVAX vector [14] to designate as
proV-IL9. The plasmids were maxi-prepared by the alkaline
method, subsequently puriﬁed by Qiagen Maxi prep kit
(Qiagen Inc., Duesseldorf, Germany), and diluted in saline
solution.
2.3.TransfectionoftheBHKCellLines. Thepuriﬁedplasmids
proV-IL9 were transfected into BHK cells with Lipofec-
tamine according to the manufacturer’s instructions (Invit-
rogen, CA, USA). The transfected cells were harvested after
48h and blocked with Fc-Block (BD Phamingen) in PBS
for 30min at 4◦C before ﬁxed with 4% paraformaldehyde
and permeabilized with saponin. Cells were intracellularly
stained with anti-IL-9-PE (BD Phamingen) for 1 hour at 4◦C
and analyzed with as FACScalibur using the Cell Quest Pro
Software (BD Bioscience).
2.4. Immunization. T h eC 5 7 B L / 6m i c ew e r er a n d o m l y
divided into ﬁve groups (6 per group), and immunized
intramuscularly on days 0, 14, and 28 listed in Table 1.
2.5. Detection of Anti-VP1-Speciﬁc Antibodies. The detection
of anti-VP1-speciﬁc antibodies in the sera was carried out
by quantitative ELISA assays as previously described [15].
The sera from immunized mice were tested individually on
day 7 after the third immunization, and the concentrations
calculated were the means of three independent assays.
2.6. Cell Proliferation. Single lymphocyte suspensions were
obtained from spleens of the mice on day 7 after the third
immunization. Cells in RPMI-1640 medium (Gibco, Eggen-
stein, Germany)/10% FBS were used to perform the cell
proliferationbyMTTmethodaftertheGST-VP1stimulation
invitrofor48h.Thismethodwasaccordingtothepreviously
describedprotocols[15].TheODval uesw e r er eadat490nm
byaplatereader(Magellan,TecanAustriaGmbH).Datawere
expressed as stimulation index (SI), calculated as the mean
readingoftriplicatewellsstimulatedwithanantigen,divided
by the mean reading of triplicate wells stimulated with the
medium.
2.7. In Vivo Cytotoxic Assay. In vivo cytotoxic assay was
performed as described previously [14] with the use of
splenocytes from na¨ ıve C57BL/6 mice pulsed with 10
−6 M
VP1 peptide and labeled with a high concentration of CFSE
(15 μM, CFSEhigh cells) as target cells. A portion of the
same splenocytes was labeled with a low concentration of
CFSE (0.5μM, CFSElow cells) without peptide pulse as a
nontarget control. The target and control cells were mixed in
a 1:1 ratio and injected into immunized mice at 2×107total
cells per mouse via the tail vein on day 7 after the third
immunization.Fourhourslater,lymphnodesandthespleens
of injected mice were removed and the target and control
cells were analyzed by their diﬀerential CFSE ﬂuorescent
intensities using an FACSCalibur (BD Biosciences, USA).
Speciﬁc lysis was calculated using the following formula:
ratio = percentage CFSElow /percentage CFSEhigh.P e r c e n t a g e
speciﬁc lysis = [1−(ratio unprimed/ratio primed) ×100].
2.8. Flow Cytometric Analysis. Splenic T cells were isolated
on day 7 after the third immunization. T cells or CD8+ T
cells from splenocytes of C57/B6 mice isolated by MACS
sorting (R&D Systems, Inc., Huntingdon Valley, PA, USA)
at 0.5 × 106 cells/20μL were stimulated in 96-well plates
with VP1 peptide (5μg/mL) and anti-CD28 (5μg/mL) mAb
f o r6 ha t3 7
◦C and 5% CO2. Monensin (2μg/mL) was
added for the last 4h and the cells were washed three times
with PBS/10%FCS. Cells were blocked with Fc-Block (BD
Phamingen,SanDiego,USA)inPBSfor30minat4oCbefore
ﬁxed with 4% paraformaldehyde and permeabilized with
saponin, immunostained with isotype controls, or double
stained with anti-CD8-FITC and anti-IFN-γ-PE, or anti-
CD8-FITC and anti-IL-17-PE, or anti-CD8-FITC and anti-
p e r f o r i n - P Ef o r1 ha t4 ◦C. The cells were washed and
analyzed with an FACScalibur using the Cell Quest Pro
Software (BD Bioscience).
2.9. RT-PCR. Total RNA was extracted from total spleno-
cytes or from sorted CD8+ T cells and then was reverse-
transcribed. Seven days after the third immunization, CD8+
T cells from splenocytes of C57/B6 mice were isolated by
MACS sorting (R&D Systems,Inc). The sequences of theJournal of Biomedicine and Biotechnology 3
M: DL2000 marker
1: the IL-9 fragment
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Figure 1: Cloning and expression of IL-9. (a) The coding sequence for mouse IL-9 was obtained from mRNA isolated from spleens. (b)
BHK cells 48h after the transfections with proV-IL9 and untransfected were collected, ﬁxed, and intracellularly stained with anti-IL-9-PE.
The results were analyzed by the FACScalibur.
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Figure 2: Eﬀect of IL-9 as adjuvant on humoral and cell proliferative responses. (a) Serum samples from six mice per immunized group
were analyzed for speciﬁc antibodies against VP1 by ELISA. Mouse IgG with a known concentration was serially diluted and a standard
curve was obtained for concentration of speciﬁc binding. (b) T cells were isolated from mice (6 per group) of all groups on day 7 after the
third immunization and stimulated with VP1 recombinant protein. A cell proliferation response was analyzed using MTT and expressed as
stimulation index. Data showed are representatives from three independent experiments.
∗P <. 05 compared with pcD-VP1 group.4 Journal of Biomedicine and Biotechnology
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Figure 3: Eﬀects of IL-9 on in vivo cytotoxic responses. (a) To analyze eﬀect of IL-9 on VP1-speciﬁc cytotoxicity, the in vivo cytotoxic assay
was performed by comparing the ratio of CSFE
high o ft a r g e tc e l l sv e r s u sC S F E
low of controls after in vivo transfer into immunized mice by
FACS. (b) The percentage of speciﬁc lysis is summarized in the means of the three independent experiments.
∗∗indicates P<. 01 between
groups.
primers are listed in Table 2. Samples were run by 1.5%
agarose gel and visualized by staining with EtBr.
2.10. Statistical Analysis. Results are presented as means ±
S.E.M. Student’s t-test analysis was used for data analysis. A
value of P< . 05 was considered to be statistically signiﬁcant.
3. Results
3.1. Cloning for IL-9 and Expression in BHK Cells. To
construct the IL-9 expression plasmid proV-IL9, the entire
mouse IL-9 cDNA (435bp) was cloned, veriﬁed by sequenc-
ing, and subcloned into the proVAX vector for eukaryotic
expression (Figure 1(a)). In order to conﬁrm proV-IL9
proteinexpressing,transfectedcellswereusedinintracellular
staining analysis by the use of anti-IL-9-PE after 48h of
the transfection. Its eukaryotic expression was observed and
showed in Figure 1(b).
3.2. IL-9 as a Molecular Adjuvant Enhances Humoral and
Cell Proliferative Responses. To examine the eﬀect of IL-9 on
the humoral response in mice, serum total IgG antibodies
against VP1 were determined by quantitative ELISA on day
7 after the third immunization. Compared to the group
immunized with pcD-VP1 plus empty vector proV, a sig-
niﬁcantly enhanced level of the production of total IgG was
found in the groups immunized with pcD-VP1 plus proV-
IL9 (Figure 2(a)). To determine whether IL-9 inﬂuences T
cell-mediatedimmunity,lymphocytesisolatedfromthemice
on day 7 after the third immunization were stimulated
with GST-VP1 protein as the speciﬁc antigen, ConA as a
positive control, BSA as a nonspeciﬁc control, and medium
as a negative control. The highest level of cell proliferation
responses was induced in the groups immunized with pcD-
V P 1p l u sp r o V - I L 9( Figure 2(b)). These data suggest that
IL-9 as molecular adjuvant increased humoral and cell
proliferative responses.
3.3. The Adjuvant Eﬀect of IL-9 on Cytotoxicity. To examine
whether proV-IL-9 could enhance antigen-speciﬁc cytotoxic
response, in vivo cytotoxic assay was performed on day 7Journal of Biomedicine and Biotechnology 5
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Figure 4: Analysis of antigen-speciﬁc cytokine productions in CD8+ T cells by FACS. (a) CD8+ T cells isolated from the spleen of C57BL/6
mice on day 7 after the ﬁnal boost were stimulated with VP1 peptide for 4 h in culture. Intracellular staining for IFN-γ, perforin, and IL-17
in CD8+ T cells was performed. (b) The summaries of percentage were shown in the means of the three independent experiments.
afterthethirdimmunization.AsshowninFigure 3,thehigh-
est percentage of antigen-speciﬁc lysis was approximately
56.3%, from the mice immunized with pcD-VP1 plus proV-
IL9, whereas it was 38.2% from the mice immunized with
pcD-VP1 plus proV.
3.4. Eﬀect of IL-9 on Cytokine Expression in CD8+ TC e l l s .
Since both IFN-γ−producing CD8+ T cells (Tc1) and IL-
17−producing CD8+ T cells (Tc17) could enhance the
cytotoxic responses [16, 17], we sought to determine which
CD8+ T cells were aﬀected by the IL-9. CD8+ Tc e l l s
were puriﬁed before used to perform the intracellular
stainings against IFN-γ,p e r f o r i n ,o rI L - 1 7o nd a y7a f t e r
the third immunization. As a representative result shown
in Figure 4(a)-4(b), the expression of antigen-induced IFN-
γ a n dp e r f o r i ni nC D 8 + T cells were signiﬁcantly higher
in the mice immunized with pcD-VP1 plus proV-IL9 than
the other groups, whereas the percentage of IL-17 in CD8+
T cells of mice immunized with pcD-VP1 plus proV-IL96 Journal of Biomedicine and Biotechnology
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Figure 5: Expression of apoptotic or proapoptotic genes in CD8+ T cells by RT-PCR. Total RNA was isolated from the splenic CD8+ Tc e l l s
of immunized on day 7 after ﬁnal boost. (a) The expression levels of apoptotic or proapoptotic genes were semiquantitatively measured
by RT-PCR through the normalization of the tested cDNA concentration to the amount of β-actin. (b), (c), (d), (e) the density of each
band as determined using Alpha image software and expressed as a relative intensity against the β-actin band. From left to right, 1, na¨ ıve; 2,
pcD/proV; 3, proV-IL9/pcD; 4, pcD-VP1/proV; 5, pcD-VP1/proV-IL9.Journal of Biomedicine and Biotechnology 7
Table 2: Target gene primers.
Target gene Primers
β-actin 5 -TGACGGGGTCACCCACACTGTGCCCATCTA
3 -CTAGAAGCATTTGCGGTGGACGATGGAGGG
BCL-2 5 -GGCTACGAGTGGGATGCT
3 -GGGTCATGTGTGTGGAGAG
BCL-XL 5 -CGATGAGTTTGAACTGCG
3 -CACCTAGAGCCTTGGATCC
BAX 5 -CTGCAGAGGATGATTGCTGA
3 -CCAACATTGCATGGTGCTAC
BLF-1 5 -CAGGGAAGATGGCTGAGTCT
3 - TTCTGCCGTATCCATTCTCC
was at the similar level with that of pcD-VP1 plus proV. It
may indicate that IL-9 favorably induces the development of
IFN-γ−producing CD8+ T cells (Tc1), not IL-17−producing
CD8+ T cells (Tc17).
3.5. IL-9 Enhanced Antiapoptotic Gene Expression in CD8+
TC e l l s .Since IL-9 could aﬀect on apoptosis [18], we
examined the eﬀect of IL-9 as adjuvant on Antiapoptotic and
proapoptotic gene expressions in CD8+ T cells on day 7 after
the third immunization. As depicted in Figure 5, the levels
of mRNAs for BCL-2 and BCL-XL induced by pcD-VP1 plus
proV-IL9 were higher, whereas the levels of mRNAs for BLF-
1a n dB A Xw e r en o ta ﬀected among the groups, indicating
that the IL-9 may enhance survival of activated CD8+ Tc e l l s
via apoptotic mechanism.
4. Discussion
O u rr e c e n ts t u d i e sd e m o n s t r a t e dt h a tI L - 9a sm o l e c u l a r
adjuvant can induce strong humoral and cellular immune
responses. Most importantly, a signiﬁcant higher level of
cytotoxic responses was observed in the mice immunized
with pcD-VP1 plus proV-IL9. In addition, IFN-γ and
perforin were up-regulated in CD8+ T cells, suggesting that
IFN-γ-producing CD8+ T cells (Tc1) were mostly aﬀected
in the cytotoxic responses. This may be owned to high
expression levels of anti-apoptosis genes of BCL-2 and BCL-
XL induced in CD8+ T cells by such adjuvant.
Immunization with DNA vaccine encoding an immuno-
genic antigen represents a novel and promising method
in vaccine research and development. Many studies have
demonstrated that the expressed antigen is naturally pro-
cessed and presented to T cells, inducing a broad range
of immune responses including antibody production and
the activation of T cells [19–22]. However, plasmid DNA
immunogenicity is relatively low compared to viral vectors;
various strategies have been proposed to enhance it, such as
molecular adjuvants.
IL-9 is a 14kDa cytokine and involved in immune
responses to helminthes as well as allergy [23, 24], it is
generally attributed to TH2c e l l s .T od a t e ,I L - 9s e e m e dt o
be associated with the Treg and TH17 cells [25–27]. Two
studies suggested that IL-9 expression in TH9 cells is distinct
from other CD4+ T cell subsets [28, 29]. Importantly, IL-
9 supports the growth of T cells and also increases the
production of IgG1 and IgE in B lymphocytes. However,
IL-9 or its expressing construct has not been tested directly
to determine what particular immune responses could be
aﬀected if it is used as a molecular adjuvant. From this
study, we observed that IL-9 as the molecular adjuvant could
increase humoral and cell proliferative responses.
Antigen-speciﬁc CTL response plays a key role in the
protection against viruses or other intracellular pathogens.
IFN-γ−producing CD8+ T cells (Tc1) and IL-17−producing
CD8+ T cells (Tc17) can enhance cytotoxic responses. Tc17
cells, a unique subset of CD8+ T cells, were found in the lung
following primary challenge with inﬂuenza A and protected
against lethal inﬂuenza challenge [30, 31]. Cytotoxicity
can be induced by two distinct molecular pathways: up-
regulation of perforin, or up-regulation of FasL (CD95L)
[32, 33]. In our study, we found that high level expressions
of IFN-γ and perforin were observed to associate with CD8+
T cells, not the IL-17. This indicates that the IL-9-induced
Tc1, but not the Tc17, enhances cytotoxic responses through
up-regulation of perforin.
In sum, our results show for the ﬁrst time that FMDV
DNA vaccine combined with IL-9 expressing plasmid can
induce strong immune responses and enhanced Tc1 medi-
ated cytotoxic responses. This IL-9 may be served as a
promising molecular adjuvant for DNA vaccinations.
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